I like the recent financial history and returns on capital, but I'm not sure about MVF due to three concerns I have:
1. Having a discount arm allows VRT to pick up more complex cases via referrals. MVF does not have this. This could possibly be remedied by setting up a deal with PRY for referrals in MVF's case, and this would be preferable to having a "discount" arm IMO.
2. Through lack of research I don't understand the contracts in place with the Specialists, and further I also don't understand if there could be benefits to the Specialists (including Embryologists) in following a "poison the well" strategy, where they might hope to be able to buy out their local operation if MVF goes South. I guess we are still quite a way away from that scenario.
3. Is there any moat at all, as the tech is quite old? I studied IVF at uni 27 years ago. Will the discount centres creep into the premium end of things? (Embryology is a different matter IMO - but not sure what MVF or VRT have in that regard that is differentiating).
I'm also curious about whether MVF have any tech advantage that allows them to open 1 or 2 clinics in every country, and win a certain amount of profitable business due to their specific advantage, or whether they are merely following a me too strategy. I really can't see how the segment analysis can be a true representation of the situation over there, unless there is no oversight of those centres or tech transfer at all from HQ. I suspect the international strategy is a eventual big loser. Esp with old tech being "commoditised" here, OS will probably follow.
- Forums
- ASX - By Stock
- Ann: Chairman's Address to Shareholders
MVF
monash ivf group limited
Add to My Watchlist
4.48%
!
70.0¢

I like the recent financial history and returns on capital, but...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
70.0¢ |
Change
0.030(4.48%) |
Mkt cap ! $271.7M |
Open | High | Low | Value | Volume |
67.5¢ | 70.0¢ | 66.5¢ | $1.679M | 2.465M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 247751 | 69.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
70.0¢ | 304403 | 35 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 247751 | 0.695 |
20 | 261178 | 0.690 |
11 | 337794 | 0.685 |
16 | 511935 | 0.680 |
10 | 787679 | 0.675 |
Price($) | Vol. | No. |
---|---|---|
0.700 | 288187 | 32 |
0.705 | 184386 | 13 |
0.710 | 460695 | 17 |
0.715 | 220088 | 4 |
0.720 | 115118 | 5 |
Last trade - 14.31pm 27/06/2025 (20 minute delay) ? |
Featured News
MVF (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online